BRPI0815415A2 - PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT - Google Patents
PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENTInfo
- Publication number
- BRPI0815415A2 BRPI0815415A2 BRPI0815415-5A2A BRPI0815415A BRPI0815415A2 BR PI0815415 A2 BRPI0815415 A2 BR PI0815415A2 BR PI0815415 A BRPI0815415 A BR PI0815415A BR PI0815415 A2 BRPI0815415 A2 BR PI0815415A2
- Authority
- BR
- Brazil
- Prior art keywords
- egfr inhibitor
- inhibitor treatment
- predictive marker
- predictive
- marker
- Prior art date
Links
- 229940121647 egfr inhibitor Drugs 0.000 title 1
- 239000003550 marker Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07114292 | 2007-08-14 | ||
| PCT/EP2008/006513 WO2009021674A1 (en) | 2007-08-14 | 2008-08-07 | Predictive markers for egfr inhibitor treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0815415A2 true BRPI0815415A2 (en) | 2015-02-03 |
Family
ID=39884813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0815415-5A2A BRPI0815415A2 (en) | 2007-08-14 | 2008-08-07 | PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2188391A1 (en) |
| JP (1) | JP2010535517A (en) |
| KR (1) | KR20100037637A (en) |
| CN (1) | CN101778954A (en) |
| AU (1) | AU2008286407A1 (en) |
| BR (1) | BRPI0815415A2 (en) |
| CA (1) | CA2695485A1 (en) |
| MX (1) | MX2010001571A (en) |
| WO (1) | WO2009021674A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120095030A1 (en) * | 2009-04-17 | 2012-04-19 | The Translational Genomics Research Institute | Methods and kits to predict therapeutic outcome of tyrosine kinase inhibitors |
| CN108732350A (en) * | 2017-04-20 | 2018-11-02 | 中国科学院上海生命科学研究院 | PLA2G6 is as tubercle and the biomarker of early warning liver cancer in instruction liver |
| CN108732351A (en) * | 2017-04-20 | 2018-11-02 | 中国科学院上海生命科学研究院 | EPS8L2 is as tubercle and the biomarker of early warning liver cancer in instruction liver |
| CN108732349A (en) * | 2017-04-20 | 2018-11-02 | 中国科学院上海生命科学研究院 | LTA4H is as tubercle and the biomarker of early warning liver cancer in instruction liver |
| CN110780072B (en) * | 2019-12-09 | 2021-08-06 | 四川大学华西医院 | Application of APOO autoantibody detection reagent in preparation of lung cancer screening kit |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
| US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5795716A (en) | 1994-10-21 | 1998-08-18 | Chee; Mark S. | Computer-aided visualization and analysis system for sequence evaluation |
| WO2001079556A2 (en) * | 2000-04-14 | 2001-10-25 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers |
| AU2004211955B2 (en) * | 2003-02-06 | 2009-05-14 | Cedars-Sinai Medical Center | Gene expression markers for response to EGFR inhibitor drugs |
| KR101126560B1 (en) * | 2003-05-30 | 2012-04-05 | 도꾜 다이가꾸 | Process for predicting drug response |
| US8093011B2 (en) | 2005-03-16 | 2012-01-10 | Haley John D | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| AR053272A1 (en) * | 2005-05-11 | 2007-04-25 | Hoffmann La Roche | DETERMINATION OF RESPONSIVES TO CHEMOTHERAPY |
| WO2007067500A2 (en) * | 2005-12-05 | 2007-06-14 | Genomic Health, Inc. | Predictors of patient response to treatment with egfr inhibitors |
-
2008
- 2008-08-07 AU AU2008286407A patent/AU2008286407A1/en not_active Abandoned
- 2008-08-07 WO PCT/EP2008/006513 patent/WO2009021674A1/en not_active Ceased
- 2008-08-07 CN CN200880103326A patent/CN101778954A/en active Pending
- 2008-08-07 JP JP2010520464A patent/JP2010535517A/en active Pending
- 2008-08-07 CA CA2695485A patent/CA2695485A1/en not_active Abandoned
- 2008-08-07 EP EP08785419A patent/EP2188391A1/en not_active Withdrawn
- 2008-08-07 MX MX2010001571A patent/MX2010001571A/en not_active Application Discontinuation
- 2008-08-07 BR BRPI0815415-5A2A patent/BRPI0815415A2/en not_active Application Discontinuation
- 2008-08-07 KR KR1020107003315A patent/KR20100037637A/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| KR20100037637A (en) | 2010-04-09 |
| WO2009021674A1 (en) | 2009-02-19 |
| CA2695485A1 (en) | 2009-02-19 |
| CN101778954A (en) | 2010-07-14 |
| JP2010535517A (en) | 2010-11-25 |
| EP2188391A1 (en) | 2010-05-26 |
| MX2010001571A (en) | 2010-03-15 |
| AU2008286407A1 (en) | 2009-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2017016I2 (en) | PROTEASOMY INHIBITORS | |
| BRPI0806898A2 (en) | Mek inhibitors | |
| EP2305306A4 (en) | NEURO-INVASION INHIBITOR | |
| BRPI0821129A2 (en) | Methods for healing inhibition | |
| BRPI0922880A2 (en) | kinase inhibitor compounds | |
| BRPI0813670A2 (en) | TREATMENT COMPOUNDS | |
| BRPI0812040A2 (en) | INDICATIONS FOR ANTI-IL-I-BETA THERAPY | |
| FR2911341B1 (en) | CORROSION INHIBITOR | |
| EP2177529A4 (en) | NEW DE-SECRETASE INHIBITOR | |
| BRPI0815415A2 (en) | PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT | |
| ATE522533T1 (en) | PYRAZOLOPYRIMIDINONKINASE INHIBITOR | |
| BRPI0814257A2 (en) | predictive marker for egfr inhibitor treatment | |
| BRPI0815545A2 (en) | PREDICTIVE MARKERS FOR TREATMENT WITH EGFR INHIBITORS | |
| BRPI0817361A2 (en) | PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT | |
| BRPI0814354A2 (en) | PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT | |
| BRPI0812105A2 (en) | NERAMEXAN FOR NISTAGM TREATMENT | |
| BRPI0715729A2 (en) | glyt-1 inhibitors | |
| BRPI0815414A2 (en) | EGFR INHIBITOR TREATMENT MARKER | |
| ES2395881T9 (en) | Predictive marker for EGFR inhibitor treatment | |
| BRPI0815546A2 (en) | PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT | |
| ES1064720Y (en) | GUIDE FOR PERSIANA | |
| FI20075320A0 (en) | New useful inhibitors | |
| BRPI0815372A2 (en) | predictive marker for egfr inhibitor treatment | |
| BRPI0821270A2 (en) | Methods for healing inhibition | |
| ES1067107Y (en) | TRAIN FOR FOOTWEAR |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |